A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable or recurrent. 2) Only subjects with positive mesothelin expression (Ventana mesothelin [MSLN]- immunohistochemistry [IHC]; Negative=H-score =< 10) are eligible. 3) Patients must have received and either progressed or been intolerant to at least 1 systemic therapy. 4) Life expectancy of at least 3 months.

You may not be eligible for this study if the following are true:

  • 1) Participation in another clinical study with an investigational product during the last 28 days or 5 half-lives prior to study Day 1, whichever is shorter. 2) Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression. 3) Any major surgery within 4 weeks of study drug administration.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.